A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative early Breast Cancer (PALLAS Study)
The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.
Primary Sponsor: Alliance Foundation Trials
Prinicipal Investigator: Lauren Mauro, M.D./Medicine; Division of Hematology/Oncology
Contact Phone: 202-677-3379
Are you interested in more information on this clinical trial?